APA (7th ed.) Citation

K, K., S, C., SD, R., V, M., & TM, V. (2026). Postmarketing Safety Concerns With FDA Black Box Warning Monoclonal Antibodies: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System Database. Journal of patient safety. https://doi.org/10.1097/PTS.0000000000001513

Chicago Style (17th ed.) Citation

K, Kalaivani, Chandrasekaran S, Rajendran SD, Munishwararaj V, and Vijayakumar TM. "Postmarketing Safety Concerns With FDA Black Box Warning Monoclonal Antibodies: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System Database." Journal of Patient Safety 2026. https://doi.org/10.1097/PTS.0000000000001513.

MLA (9th ed.) Citation

K, Kalaivani, et al. "Postmarketing Safety Concerns With FDA Black Box Warning Monoclonal Antibodies: A Pharmacovigilance Study Based on the FDA Adverse Event Reporting System Database." Journal of Patient Safety, 2026, https://doi.org/10.1097/PTS.0000000000001513.